# US 2004/0082531 A1 · Dna expression vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082531 A1
- Document ID: US20040082531A1
- Status: Published application
- Kind: A1
- Application number: 10/415,999
- Filed: 2003-10-29
- Published: 2004-04-29
- Earliest claimed: 2000-11-06
- Inventors: Ian Richard Catchpole; Jonathan Henry Ellis; Peter Franz Ertl; John Richard Rhodes
- Web page: https://patentgrep.com/patent/US20040082531A1

## CPC

- C12N 15/85: for animal cells
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2710/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to DNA vectors containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A. Vectors, host cells, pharmaceutical and vaccine compositions comprising such host cells and vectors are contemplated.

## Claims

### Claim 1

A vector containing a DNA sequence comprising a promoter and a fragment of the 5′ untranslated region of the HCMV IE1 gene including substantially all of exon 1 but excluding substantially all of intron A.

### Claim 2 (depends on 1)

A vector according to claim 1 wherein the promoter is an HCMV IE1 minimal promoter.

### Claim 3 (depends on 1, 2)

A vector according to claim 1 or claim 2 wherein the fragment of the of the 5′ untranslated region of the HCMV IE1 gene is positioned immediately 3′ to the promoter.

### Claim 4 (depends on 3)

A vector according to claim 3 which further comprises a heterologous intron sequence other than intron A of the HCMV IE1 gene positioned immediately downstream of HCMV IE1 exon 1 in the 5′ untranslated region.

### Claim 5 (depends on 3, 4)

A vector according to claim 3 or claim 4 which further comprises one or more restriction sites positioned downstream of the 5′ untranslated region.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A vector according to any one of claims 1 to 5 which is plasmid vector.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A vector according to any one of claims 1 to 6 which is an expression vector for use in expression of a polypeptide in a eukaryotic host cell or organism.

### Claim 8 (depends on 7)

An expression vector according to claim 7 which comprises a DNA sequence encoding a polypeptide operably linked to the promoter and HCMV IE1 5′ untranslated region.

### Claim 9 (depends on 8)

An expression vector according to claim 8 wherein the polypeptide is an antigenic peptide.

### Claim 10 (depends on 9)

An expression vector according to claim 9 for use as a vaccine or immunotherapeutic or as a component of a vaccine composition or immunotherapeutic composition.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

An immunogenic composition comprising a vector according to claim 1 to 10 and a pharmaceutically acceptable adjuvant diluent, excipient or carrier.

### Claim 12 (depends on 11)

A composition according to claim 11 which carrier comprises a bead onto which the vector is coated.

### Claim 13 (depends on 9)

Use of an expression vector according to claim 9 for the manufacture of a vaccine, immunotherapeutic, vaccine composition or immunotherapeutic composition.

### Claim 14 (depends on 9, 11, 12)

A method of vaccinating a human subject which comprises administering to said subject an effective amount of a vaccine or vaccine composition comprising an expression vector according to claim 9, or composition according to claim 11 or 12.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A host cell transformed or transfected with an expression vector according to claim 1 to 10.

### Claim 16 (depends on 8, 9)

A process for the production of a recombinant polypeptide in a eukaryotic host cell, comprising introducing an expression vector according to claim 8 or claim 9 into the host cell under conditions which allow for expression of the polypeptide.
